Analysts have been eager to weigh in on the Healthcare sector with new ratings on Clearside Biomedical (CLSD) and Avrobio Inc (AVRO).
Clearside Biomedical (CLSD)
In a report released today, Boris Peaker from Cowen & Co. maintained a Hold rating on Clearside Biomedical. The company’s shares opened today at $1.12, close to its 52-week low of $0.99.
According to TipRanks.com, Peaker is a 4-star analyst with an average return of 4.1% and a 41.5% success rate. Peaker covers the Healthcare sector, focusing on stocks such as Iovance Biotherapeutics Inc, Corvus Pharmaceuticals Inc, and Stemline Therapeutics Inc.
Currently, the analyst consensus on Clearside Biomedical is a Moderate Buy with an average price target of $4.83.
See today’s analyst top recommended stocks >>
Avrobio Inc (AVRO)
Cowen & Co. analyst Ritu Baral maintained a Buy rating on Avrobio Inc today. The company’s shares opened today at $13.50, close to its 52-week low of $12.30.
According to TipRanks.com, Baral is a top 100 analyst with an average return of 24.6% and a 47.7% success rate. Baral covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals Inc, Allena Pharmaceuticals Inc, and Global Blood Therapeutics.
Avrobio Inc has an analyst consensus of Moderate Buy, with a price target consensus of $40, implying a 196.3% upside from current levels. In a report issued on January 15, H.C. Wainwright also maintained a Buy rating on the stock with a $40 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
